ABCC2 and triple-negative breast carcinoma: When the three triple negative breast cancer lines were treated with the IC50 dose of doxorubicin, it caused a greater than 3-fold induction of ABCC2 in MDA-MB-231 and HDQ-P1 cells, and a modest but statistically significant increase in MDA-MB-468 cells.